Mantadin 100mg

Amantadine Hydrochloride has direct and indirect effects on dopamine neurons. It acts on the pre-synaptic membrane, enhancing the release of dopamine and inhibiting its reuptake. Post-synaptically, Amantadine acts directly on the dopamine receptor, and up regulates D2 receptors. This may be due to Amantadine-induced hypersensitivity of dopamine receptors. It has antimuscarinic properties. Amantadine also has antiglutamatergic properties, via non-competitive antagonism of NMDA receptors. Furthermore, potent, competitive, non-subunit selective NMDA receptor antagonists reduce the severity of levodopa-induced dyskinesias. NMDA receptor sensitization may be a key event in the genesis of levodopa-induced dyskinesias. It also has immunomodulatory properties. It restores the production of interleukin-2 (IL-2), which is defective in Parkinson’s disease patients. The mechanism by which Amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. Amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine.

Parkinson’s disease–

• Adults: The usual dose is 100 mg twice a day when used alone.
• The initial dose of Amantadine is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.
• Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 400 mg daily in divided doses.
• Dosage for Concomitant Therapy: Some patients who do not respond to anticholinergic antiparkinson drugs may respond to Amantadine.
• When Amantadine or anticholinergic antiparkinson drugs are each used with marginal benefit, concomitant use may produce additional benefit. When Amantadine and levodopa therapy are initiated concurrently, the patient can exhibit rapid therapeutic benefits. Amantadine dose, should be held constant at 100 mg daily or twice daily while the daily dose of levodopa is gradually increased to optimal benefit.
• When Amantadine is added to optimal well-tolerated doses of levodopa, additional benefit may result, including smoothing out the fluctuations in improvement which sometimes occur in patients on levodopa alone. Patients who require a reduction in their usual dose of levodopa because of development of side effects may possibly regain lost benefit with the addition of Amantadine.

Drug-induced extrapyramidal reactions–

• Adults: The usual dose is 100 mg twice a day.
• Occasionally, patients whose responses are not optimal with Amantadine at 200 mg daily may benefit from an increase up to 300 mg daily in divided doses.

Prophylaxis and treatment of Influenza A virus illness–

• Adults: 200 mg/day as single dose or 100 mg twice daily. If CNS effects develop on a once- daily dosage, split dosage schedule may reduce complaints.
• Elderly over 65 years of age: 100 mg every day.
• Children: 1 to 9 years of age: 4.4 to 8.8 mg/kg/day; not to exceed 150 mg/day. 9 to 12 years of age: 100 mg twice daily

Method of administration: Each capsule is to be taken orally either with or without food.

Patients with renal impairment: The dose should be reduced. This can be achieved by either reducing the total daily dose, or by increasing the dosage interval in accordance with the creatinine clearance.

Patients with hepatic impairment: Use with caution.